Related references
Note: Only part of the references are listed.Simultaneous determination of rifampicin, clarithromycin and their metabolites in dried blood spots using LC-MS/MS
D. H. Vu et al.
TALANTA (2014)
Comparison of Levofloxacin versus Moxifloxacin for Multidrug-Resistant Tuberculosis
Won-Jung Koh et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2013)
Isoniazid, Rifampin, and Pyrazinamide Plasma Concentrations in Relation to Treatment Response in Indonesian Pulmonary Tuberculosis Patients
Erlina Burhan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy
Junichi Azuma et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
PA-824, moxifloxacin and pyrazinamide combination therapy for tuberculosis
Rodney Dawson et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: a meta-analysis
T. J. Hwang et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2013)
Therapeutic drug monitoring in the treatment of tuberculosis: a retrospective analysis
L. Van Tongeren et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2013)
Systematic review of clofazimine for the treatment of drug-resistant tuberculosis
M. Gopal et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2013)
Pharmacokinetics and serum concentrations of antimycobacterial drugs in adult Turkish patients
A. Babalik et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2013)
Serum Drug Concentrations Predictive of Pulmonary Tuberculosis Outcomes
Jotam G. Pasipanodya et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Randomized Clinical Trial of Thrice-Weekly 4-Month Moxifloxacin or Gatifloxacin Containing Regimens in the Treatment of New Sputum Positive Pulmonary Tuberculosis Patients
Mohideen S. Jawahar et al.
PLOS ONE (2013)
High Rate of Hypothyroidism in Multidrug-Resistant Tuberculosis Patients Co-Infected with HIV in Mumbai, India
Aristomo Andries et al.
PLOS ONE (2013)
New Susceptibility Breakpoints and the Regional Variability of MIC Distribution in Mycobacterium tuberculosis Isolates
Jotam Pasipanodya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Linezolid in Patients with Multidrug-Resistant Tuberculosis
D. H. Vu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Reduced Antituberculosis Drug Concentrations in HIV-Infected Patients Who Are Men or Have Low Weight: Implications for International Dosing Guidelines
Helen McIlleron et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Meta-Analysis of Clinical Studies Supports the Pharmacokinetic Variability Hypothesis for Acquired Drug Resistance and Failure of Antituberculosis Therapy
Jotam G. Pasipanodya et al.
CLINICAL INFECTIOUS DISEASES (2012)
Effect of Diabetes Mellitus on Pharmacokinetic and Pharmacodynamic Properties of Drugs
Miroslav Dostalek et al.
CLINICAL PHARMACOKINETICS (2012)
Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis
Giovanni Sotgiu et al.
EUROPEAN RESPIRATORY JOURNAL (2012)
Antituberculosis therapy for 2012 and beyond
Michael Lauzardo et al.
EXPERT OPINION ON PHARMACOTHERAPY (2012)
Frequency of adverse reactions to first- and second-line anti-tuberculosis chemotherapy in a Korean cohort
M. W. Carroll et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2012)
Substitution of Rifapentine for Rifampin During Intensive Phase Treatment of Pulmonary Tuberculosis: Study 29 of the Tuberculosis Trials Consortium
Susan E. Dorman et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis
L. Ben Mahmoud et al.
PATHOLOGIE BIOLOGIE (2012)
Therapeutic drug monitoring in the treatment of tuberculosis patients
Cecile Magis-Escurra et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2012)
An Oracle: Antituberculosis Pharmacokinetics-Pharmacodynamics, Clinical Correlation, and Clinical Trial Simulations To Predict the Future
Jotam Pasipanodya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Dose-Dependent Activity of Pyrazinamide in Animal Models of Intracellular and Extracellular Tuberculosis Infections
Zahoor Ahmad et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Therapeutic drug monitoring in the treatment of active tuberculosis
Aylin Babalik et al.
CANADIAN RESPIRATORY JOURNAL (2011)
In Vitro and In Vivo Modeling of Tuberculosis Drugs and its Impact on Optimization of Doses and Regimens
Shashikant Srivastava et al.
CURRENT PHARMACEUTICAL DESIGN (2011)
Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience
A. D. Pranger et al.
EUROPEAN RESPIRATORY JOURNAL (2011)
Multidrug-Resistant Tuberculosis Not Due to Noncompliance but to Between-Patient Pharmacokinetic Variability
Shashikant Srivastava et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection
Timothy R. Sterling et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Limited-Sampling Strategies for Therapeutic Drug Monitoring of Moxifloxacin in Patients With Tuberculosis
Arianna D. Pranger et al.
THERAPEUTIC DRUG MONITORING (2011)
Treatment of tuberculosis and optimal dosing schedules
Kwok Chiu Chang et al.
THORAX (2011)
Pharmacokinetics of Antituberculosis Drugs in Pulmonary Tuberculosis Patients with Type 2 Diabetes
Rovina Ruslami et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Clinical and Toxicodynamic Evidence that High-Dose Pyrazinamide Is Not More Hepatotoxic than the Low Doses Currently Used
Jotam G. Pasipanodya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Comparison of the Pharmacokinetics of Two Dosage Regimens of Linezolid in Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis Patients
Jan-Willem C. Alffenaar et al.
CLINICAL PHARMACOKINETICS (2010)
Limited Sampling Strategies for Therapeutic Drug Monitoring of Linezolid in Patients With Multidrug-Resistant Tuberculosis
Jan-Willem C. Alffenaar et al.
THERAPEUTIC DRUG MONITORING (2010)
Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA
Scott K. Heysell et al.
EMERGING INFECTIOUS DISEASES (2010)
Substitution of Moxifloxacin for Isoniazid during Intensive Phase Treatment of Pulmonary Tuberculosis
Susan E. Dorman et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2009)
Pharmacokinetics-Pharmacodynamics of Pyrazinamide in a Novel In Vitro Model of Tuberculosis for Sterilizing Effect: a Paradigm for Faster Assessment of New Antituberculosis Drugs
Tawanda Gumbo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Pharmacokinetic Evaluation of Rifabutin in Combination with Lopinavir-Ritonavir in Patients with HIV Infection and Active Tuberculosis
Catherine Boulanger et al.
CLINICAL INFECTIOUS DISEASES (2009)
Isoniazid, Rifampin, Ethambutol, and Pyrazinamide Pharmacokinetics and Treatment Outcomes among a Predominantly HIV-Infected Cohort of Adults with Tuberculosis from Botswana
Sekai Chideya et al.
CLINICAL INFECTIOUS DISEASES (2009)
Tuberculosis and diabetes mellitus: convergence of two epidemics
Kelly E. Dooley et al.
LANCET INFECTIOUS DISEASES (2009)
Therapeutic Drug Monitoring of Antimycobacterial Drugs in Patients with Both Tuberculosis and Advanced Human Immunodeficiency Virus Infection
David P. Holland et al.
PHARMACOTHERAPY (2009)
Dried Blood Spot Methods in Therapeutic Drug Monitoring: Methods, Assays, and Pitfalls
Peter M. Edelbroek et al.
THERAPEUTIC DRUG MONITORING (2009)
Risk factors for ethambutol optic toxicity
Katherine Anne Talbert Estlin et al.
INTERNATIONAL OPHTHALMOLOGY (2009)
Repeated Administration of High-Dose Intermittent Rifapentine Reduces Rifapentine and Moxifloxacin Plasma Concentrations
Kelly Dooley et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Concomitant use of voriconazole and rifabutin in a patient with multiple infections
Joshua N. Schwiesow et al.
PHARMACOTHERAPY (2008)
Using animal models to develop new treatments for tuberculosis
Eric Nuermberger
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs
G. R. Davies et al.
TUBERCULOSIS (2008)
Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis
Charles A. Peloquin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin
Tawanda Gumbo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis
Hyun-Jung Cho et al.
TUBERCULOSIS (2007)
Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis
H. M. J. Nijland et al.
CLINICAL INFECTIOUS DISEASES (2007)
Location of persisting mycobacteria in a guinea pig model of tuberculosis revealed by R207910
Anne J. Lenaerts et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis
Bachti Alisjahbana et al.
CLINICAL INFECTIOUS DISEASES (2007)
Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin
Marc Weiner et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears
A. H. Diacon et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection
Debra A. Benator et al.
PHARMACOTHERAPY (2007)
Fluoroquinolones for the treatment of pulmonary tuberculosis
Susanne Moadebi et al.
DRUGS (2007)
Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes
Hanneke M. J. Nijland et al.
CLINICAL INFECTIOUS DISEASES (2006)
Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis
I-Nae Park et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2006)
Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients
H McIlleron et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Evaluation of high- versus standard-dose rifampin in Indonesian patients with pulmonary tuberculosis
R Ruslami et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Evidence of tendinitis provoked by fluoroquinolone treatment - A case-control study
Giovanni Corrao et al.
DRUG SAFETY (2006)
Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis
M Weiner et al.
CLINICAL INFECTIOUS DISEASES (2005)
Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana
JW Tappero et al.
CLINICAL INFECTIOUS DISEASES (2005)
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis
M Weiner et al.
CLINICAL INFECTIOUS DISEASES (2005)
Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections
E Nuermberger et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2004)
Isoniazid pharmacokinetics-pharmaco dynamics in an aerosol infection model of tuberculosis
R Jayaram et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Use of therapeutic drug monitoring for multidrug-resistant tuberculosis patients
JH Li et al.
CHEST (2004)
Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling
T Gumbo et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease
P Gurumurthy et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
M-tuberculosis persistence, latency, and drug tolerance
JE Gomez et al.
TUBERCULOSIS (2004)
Action of fluoroquinolones and linezolid on logarithmic- and stationary-phase culture of Mycobacterium tuberculosis
A Garcia-Tapia et al.
CHEMOTHERAPY (2004)
Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis
R Jayaram et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine
M Weiner et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2003)
Managing antituberculosis drug therapy by therapeutic drug monitoring of rifampicin and isoniazid
J Ray et al.
INTERNAL MEDICINE JOURNAL (2003)
Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid
Y Zhang et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2003)
Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme
CR Rayner et al.
CLINICAL PHARMACOKINETICS (2003)
In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis
JC Rodríguez et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2002)
In vivo pharmacodynamics of a new oxazolidinone (linezolid)
D Andes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Limited tolerability of levofloxacin and pyrazinamide for multidrug-resistant tuberculosis prophylaxis in a solid organ transplant population
HX Lou et al.
PHARMACOTHERAPY (2002)
Therapeutic drug monitoring in HIV infection: current status and future directions
D Back et al.
AIDS (2002)
Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy
JB Mehta et al.
CHEST (2001)
Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis
M Zhu et al.
PHARMACOTHERAPY (2001)
Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids
M Zhu et al.
PHARMACOTHERAPY (2001)
Tuberculosis: Latency and reactivation
JL Flynn et al.
INFECTION AND IMMUNITY (2001)
Pharmacokinetics of ethionamide administered under fasting conditions or with orange juice, food, or antacids
B Auclair et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2001)
An argument for routine therapeutic drug monitoring of HIV-1 protease inhibitors during pregnancy
JB Angel et al.
AIDS (2001)
The role of fluoroquinolones in tuberculosis today
SE Berning
DRUGS (2001)
The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis
A Somoskovi et al.
RESPIRATORY RESEARCH (2001)
Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials
WJ Burman et al.
CLINICAL PHARMACOKINETICS (2001)
Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection
R Hernández-Pando et al.
LANCET (2000)
Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects
JL Démolis et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2000)
Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study
J Durant et al.
AIDS (2000)
Use of rifabutin with protease inhibitors for human immunodeficiency virus-infected patients with tuberculosis
M Narita et al.
CLINICAL INFECTIOUS DISEASES (2000)
Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis
O Zimhony et al.
NATURE MEDICINE (2000)
Share Paper
